Allogene Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Allogene issued a business update and financial results for the 3rd quarter of 2026, but the call did not state specific financial figures.
- Management said ALPHA-3’s interim futility analysis earlier this year showed rapid MRD clearance, a favorable early safety profile, and the feasibility of administering CEMACELT in community practices, including centers with no prior CAR-T experience.
- Management reported increased MRD screening, stronger investigator engagement, and brisk enrollment activity in the Asia-Pacific region, particularly Korea and Australia.
- For ALLO-329, management said that to date there had been no high-grade toxicities or cases of IECHS, and described the observed safety profile as encouraging.
- Management said scleroderma had become the most active enrollment pathway in ALLO-329’s basket trial, while patients with lupus and myositis remained eligible.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please be advised that today's conference is being recorded. I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead.
Thank you, operator, and welcome everyone to Allogene's conference call. After the market closed, Allogene issued a press release that provided a business update and financial results for the third quarter of 2026. This press release and today's webcast are available on our website. Following brief prepared remarks from Dr. Zachary Roberts, President and Chief Executive Officer, we will open the call for questions. Geoff Parker, Chief Financial Officer, will also join the Q&A. To keep the call within 45 minutes, please limit questions to one per analyst. During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, commercial market forecasts, the potential treatment settings, and financial guidance, among other things.
These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can be found in our press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements. I'll now turn the call over to Zach.
Thanks, Christine, and good afternoon, everyone. Before we begin, I want to recognize Geoff Parker, who retires tomorrow after serving as CFO through some of Allogene's most consequential years. Geoff helped us navigate change and maintain the financial discipline that positions us for the future. Geoff, thank you, and we wish you the best in retirement. As our search for a new CFO continues, we have full confidence in our financial operations and controls under Annie Yoshiyama, our SVP of Finance, Corporate Controller, and Principal Accounting Officer. Annie brings 20 years of experience and has played a key role in our financial reporting and financing activities since joining in 2024. Finding the right CFO is especially important as we enter this next chapter where the strategic decisions we've made could create meaningful new opportunities for Allogene.
When I joined Allogene, my mandate was to challenge how we were developing allogeneic CAR-T. We had an extraordinary technology, but technology alone wasn't enough. We needed to start with patients and work backward. What barriers prevented them from receiving CAR-T? How could an off-the-shelf product remove those barriers? CAR-T has transformed what's possible in medicine, but nearly a decade into the commercial CAR-T era, the realities of delivering CAR-T continue to limit who benefits. We've seen other allogeneic programs stop or change course. Investor confidence in cell therapy has eroded as companies pursue highly similar strategies without overcoming the fundamental obstacles. The challenges facing the industry today are the very ones Allogene anticipated and made difficult strategic decisions to address in 2024.
With our deep experience in cell therapy, we recognized that following the traditional late-line development pathway with cema-cel was unlikely to unlock the full potential of allogeneic CAR-T. Meanwhile, advances in diagnostics created an opportunity to identify patients at risk of relapse before their disease returned clinically and created a compelling need for off-the-shelf CAR-T. The real opportunity wasn't simply to develop a different kind of CAR-T, but to rethink where and when CAR-T could make the greatest difference. It gave us a chance to address a distinct area of unmet medical need, MRD-positive lymphoma, and potentially change the course of treatment for patients who might otherwise face the uncertainty of relapse. We believe this strategy could make a meaningful difference for patients, and we saw it as a compelling path forward for Allogene. We weren't simply looking for a better way to deliver CAR-T.
We were looking for a better moment to use it, and that is why I believe it's time to look at Allogene through a different lens. ALPHA3 is testing whether we can fundamentally change when, where, and how patients receive CAR-T. Our interim futility analysis earlier this year provided encouraging evidence of rapid MRD clearance, a favorable early safety profile, and the feasibility of administering cema-cel in community practices, even at centers with no prior CAR-T experience. Enrollment momentum continues, supported by increased MRD screening, strong investigator engagement, and brisk activity in the Asia-Pacific region. As our trial network expands, we're seeing growing engagement across participating sites. In 2027, we look forward to our next clinical update mid-year and enrollment completion by year-end. We continue to watch the evolution of first-line lymphoma treatment closely, including the recent phase III results with novel regimens.
Better outcomes are always welcome, but safety and practical demands of treatment matter too. Even with reimbursement, the complexity and cost of administering therapy can challenge providers. R-CHOP, along with the recently approved Pola-R-CHP regimen, has been dominant for 25 years, not only because they work well, but because they are safe, well-tolerated, and practical to deliver in community settings. This is why we are looking beyond clinical development. We're challenging assumptions built around autologous CAR-T, from treatment site requirements to the infrastructure needed to deliver therapy. Our view of value encompasses the total cost of care, the burden on patients and caregivers, and the economics of treatment delivery. From reimbursement to site readiness, we're building a model that reflects the distinct characteristics of allogeneic CAR-T and its potential to make treatment more accessible.
At ASH, we will share findings from our survey of 152 U.S. hematologists and oncologists examining the barriers that continue to limit CAR T adoption. We will also host an investor event exploring how cema-cel could potentially address those barriers. That same focus on overcoming barriers extends to ALLO-329. In a few days, we will present our first clinical results at the American College of Rheumatology annual meeting, or ACR. This update will offer an early glimpse into whether our deliberate choices in designing ALLO-329 and its clinical trial are translating into meaningful benefits for patients. Safety is particularly important. Recent events across autoimmune CAR T programs have reinforced the need to carefully balance therapeutic benefit with treatment risk. Our experience with ALLO-316 taught us difficult but important lessons about managing inflammatory toxicities, including IEC-HS.
We worked closely with experts and the FDA to develop detailed monitoring and management guidance, and carried those lessons directly into the RESOLUTION protocol from the outset. To date, we have observed no high-grade toxicities or cases of IEC-HS with ALLO-329. Our approach is more than managing toxicity. ALLO-329 was designed with our DAGGER technology to address allogeneic rejection, with the potential to reduce reliance on chemotherapy-based lymphodepletion. That is particularly important in autoimmune disease, where balancing benefit, toxicity, and treatment burden is critical. On November 9, we will present an expanded clinical and translational dataset at ACR, including additional patients, longer follow-up, three dose levels, and three conditioning approaches. We will be looking closely at what the data tell us about CAR T activity and clinical responses across different conditioning approaches.
One of the most important questions is whether DAGGER can help us achieve meaningful activity while reducing the chemotherapy burden traditionally associated with CAR T. That is a potentially important distinction, particularly in autoimmune disease. We are very interested in what we are seeing in scleroderma, which has emerged as the most active pathway to enrollment in our basket design. While patients with lupus or myositis remain eligible for RESOLUTION, we are becoming more deliberate about prioritizing indications where ALLO-329 could offer the greatest differentiation. The lessons we are learning across these programs are also informing the next generation of our platform. That work will be featured at SITC, including our clinical experience with ALLO-316 in renal cell carcinoma and preclinical findings from our DLL3/CD70 dual CAR T program. Across our programs, we have made deliberate choices, applied what we have learned, and invested in a different model for CAR T.
In a field driven by the next breakthrough, we know that innovation is only the beginning. The real achievement is making it work in the real world. That is what we have spent years building towards, and as we look into 2027, we believe our clinical data could begin to demonstrate the value of those decisions. What comes next has the potential to be far more exciting than the science that first captured everyone's imagination, because innovation only matters if patients can access it. We will now open the call for questions.
Thank you. As a reminder, to ask a question, simply press star 11 on your telephone and wait for your name to be announced. To remove yourself, press star 11 again. We ask that you please keep your questions to one. One moment, please. Our first question is from Tyler Van Buren with TD Cowen.
Please proceed. Hey, guys. Thanks for taking the question.
Could you just discuss your ongoing confidence again in administering cema-cel in the outpatient setting and at community practices, especially those with no prior CAR T experience? You discussed this a little bit during the prepared remarks, but it would be great to elaborate on that and how you teach and educate them to adopt the appropriate protocols and patient monitoring.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
16 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
